#endocrinetherapy
LightNews LightNews
yalecancer.bsky.social
Dr. Lajos Pusztai shares a presentation on ctDNA monitoring of ER+ HER2- high-risk #breastcancer during adjuvant #endocrinetherapy today at 4:54pm CDT #ASCO25.
meetings.asco.org/2025-asco-an...
@yaleschoolofmed.bsky.social
June 1, 2025 at 9:21 PM
dfcibreastonc.bsky.social
The COMET Randomized Clinical Trial on Active Monitoring With or Without #EndocrineTherapy for Low-Risk #DuctalCarcinomaInSitu was recently published in JAMA, check it out here: pubmed.ncbi.nlm.nih.gov/39665585/
January 13, 2025 at 3:35 PM
bigxresearch.bsky.social
#ESMO25 The latest results from the #POSITIVE study show that temporary interruption of #endocrinetherapy for pregnancy does not add risk of #breastcancer recurrence at 6 yrs median FU. Most pts resumed ET per protocol. @etop_ibcsg @OncoAlert @oncodaily
October 17, 2025 at 1:03 PM
thecancersurvivorsclub.com
Breast cancer survivors reaching the 5-year mark after endocrine therapy face key decisions on next steps. Expert advice helps guide treatment choices & improve long-term outcomes. #TCSC #BreastCancer #CancerSurvivorship #Oncology #EndocrineTherapy #Cancer

www.oncnursingnews.com/view/making-...
Making Breast Cancer Treatment Decisions After Endocrine Therapy
A breast cancer survivorship expert shares her top advice for counseling patients on endocrine therapy at the 5-year mark.
www.oncnursingnews.com
August 15, 2025 at 7:59 AM
onco404.bsky.social
A large National Cancer Database study reveals endocrine therapy (ET) improves survival in early-stage ER-low (1%-10%) breast cancer, even after chemo.

@ascocancer.bsky.social #JCO @breastcancernow.bsky.social

#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #Oncology #EndocrineTherapy
May 3, 2025 at 4:48 PM
thelancetoncol.bsky.social
New—overall survival results from Young-PEARL:

#Palbociclib plus #endocrinetherapy versus capecitabine in #premenopausal women with hormone receptor-positive, HER2-negative metastatic #breastcancer
buff.ly
February 18, 2025 at 1:00 PM
onco404.bsky.social
📌 Here's OncoTerm - Word of the Day! 👋

📌 OncoTerm - Günün Kelimesi! 👋

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.

#Onco404 #Cancer #Kanser #MedSky #OncSky #CancerAwareness #BreastCancer #ProstateCancer #Hormone #EndocrineTherapy #Vocabulary
April 25, 2025 at 5:39 AM
combinedstrategies.bsky.social
Study: Don't Quit HT, There Are Strong Overall Survival (OS) Benefits Shown for HR+ eBC Patients. #powerofhormonetherapy #endocrinetherapy
ascopost.com/news/april-2...
Omission of Endocrine Therapy in Estrogen Receptor–Low, Early-Stage Breast Cancer
In a study reported in the Journal of Clinical Oncology, Choong et al looked at whether the omission of endocrine therapy in patients with estrogen receptor–low (1%–10% on immunohistochemistry), early...
ascopost.com
April 29, 2025 at 12:38 AM
rcatanho.bsky.social
En CA mama en estadío temprano c/rec estrogénico bajo, omisión de la terapia endocrina se asocia con peor supervivencia general, especialmente en enfermedad residual luego de quimioterapia neoadyuvante y con receptor estrogénico 6 a 10% #endocrinetherapy #breastcancer ascopubs.org/doi/abs/10.1...
Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer
PURPOSEAdjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%)...
ascopubs.org
June 2, 2025 at 8:34 AM
bigxresearch.bsky.social
Proffered paper presentation by Paul Cottu of the #RIBOLARIS trial at #ESMO25 showed that a subset of pts with HR+/HER2− eBC achieved ROR-low disease after neoadjuvant #ribociclib + #endocrinetherapy suggesting they could potentially avoid chemotherapy @_SOLTI @unicancer @OncoAlert
October 17, 2025 at 12:30 PM
bigxresearch.bsky.social
#ASCO25: Assessment of #breastcancer Index benefit in #premenopausal pts receiving OFS-containing adjuvant #endocrinetherapy was compared btw #SOFT&TEXT cohorts and validation of the prognostic performance of BCI was conducted, go check Poster #150
@etop_ibcsg
@oreganruth
June 2, 2025 at 2:30 PM
annsurgoncology.bsky.social
July Issue: Differential Effects of #EndocrineTherapy Type on #QualityOfLife in Older (≥70 Years) Women with Early‑Stage #BreastCancer

rdcu.be/euaFI
July 1, 2025 at 3:27 PM
arxivlens.bsky.social
Endocrine therapy induces oxidative stress in ER+ breast cancer that sensitizes persister cells to ferroptosis
Cressey, L., Ferridge, L. R. et al.
Paper
Details
#EndocrineTherapy #ERPositiveBreastCancer #FerroptosisResearch
July 24, 2025 at 4:02 PM
dfcibreastonc.bsky.social
Learn more about the CAMBRIA-1 & CAMBRIA-2 phase III trials on #camizestrant versus standard #EndocrineTherapy in ER+/HER2- early #BreastCancer.
🔓https://pubmed.ncbi.nlm.nih.gov/40017004/
✍️@erikahamilton9.bsky.social @michaelgnant.bsky.social
@stolaney1.bsky.social @barbarapistill2.bsky.social
March 25, 2025 at 6:00 PM
bigxresearch.bsky.social
New pub 📢 The #POSITIVEtrial manuscript led by @IDemeestere has been published in The Breast! It explores hormonal factors predictive of fertility in young women with #breastcancer interrupting #endocrinetherapy to try for pregnancy. @etop_ibcsg

🔗 www.thebreastonline.com/article/S096...
August 19, 2025 at 10:30 AM
combinedstrategies.bsky.social
"Results show unmet need remains despite standard-of-care endocrine therapy." Study of note. "This real-world study ... confirms the need for improved treatment options." BC PATIENTS NEED BETTER TREATMENT OPTIONS ASAP! #hormonetherapy #endocrinetherapy
www.thebreastonline.com/article/S096...
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer
Despite adjuvant endocrine therapy (ET), recurrence is still a concern for patients with HR+/HER2- early breast cancer (EBC). We assessed recurrence risk in real-world patients with stage II/III HR+/H...
www.thebreastonline.com
April 20, 2025 at 12:49 AM
bigxresearch.bsky.social
NOW at #ESMOBreast25! A presentation by @fedrophd on predictive factors of #fertility in pts w/ #breastcancer interrupting #adjuvant #endocrinetherapy to attempt pregnancy in the #POSITIVE Trial @etop_ibcsg @alliance_trials
May 14, 2025 at 3:17 PM
dfcibreastonc.bsky.social
Join Dr. Ann Partridge in the #SABCS24 General Session 2 as she discusses patient-reported outcomes from the COMET Study (AFT-25), comparing active monitoring versus surgery (+/- radiation) with or without #EndocrineTherapy for low-risk #DCIS.
December 11, 2024 at 6:32 PM
myesmo.bsky.social
#ESMO25: The combination giredestrant+everolimus showed a 44% reduction in risk of progression compared to #endocrinetherapy+everolimus in pts with ER-positive, HER2-negative advanced #BreastCancer previously treated w/ CDK4/6-inhibitors.

#ESMODailyReporter ➡️https://ow.ly/zJ6c50XmoHT

November 5, 2025 at 3:35 PM
bigxresearch.bsky.social
Today at #ESMO25, Dr. Fedro A Peccatori will present the updated results of #POSITIVEtrial after 5 years FU of pts w/ HR+ who have temporarily interrupted #endocrinetherapy to attempt #pregnancy. @etop_ibcsg
October 17, 2025 at 12:03 PM